Inventor · disambiguated record
Steven G. Nadler
Also filed as: NADLER STEVEN · NADLER STEVEN G
26 granted patents·17 pending applications·241 citations·filing 1997–2025
96Inventor score
Top patents by PatentIndex Score
43 records- 0194US8895010B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Nov 25, 2014·24 cites·36 claims
- 0293US8454959B2Compositions monovalent for CD28 binding and methods of useMCKINNON MURRAY·Filed 2012·Granted Jun 4, 2013·23 cites·11 claims
- 0393US8168759B2Compositions monovalent for CD28 binding and methods of useMCKINNON MURRAY·Filed 2009·Granted May 1, 2012·21 cites·13 claims
- 0492US12239710B2FN3 domain-siRNA conjugates and uses thereofAro Biotherapeutics Company·Filed 2022·Granted Mar 4, 2025·2 cites·57 claims
- 0592US11628222B2CD71 binding fibronectin type III domainsAro Biotherapeutics Company·Filed 2020·Granted Apr 18, 2023·5 cites·34 claims
- 0692US9085629B2Compositions monovalent for CD28 binding and methods of useMCKINNON MURRAY·Filed 2012·Granted Jul 21, 2015·18 cites·29 claims
- 0791US12037379B2CD71 binding fibronectin type III domainsAro Biotherapeutics Company·Filed 2022·Granted Jul 16, 2024·2 cites·20 claims
- 0891US11781138B2FN3 domain-siRNA conjugates and uses thereofAro Biotherapeutics Company·Filed 2020·Granted Oct 10, 2023·4 cites·36 claims
- 0991US10919965B2Compositions monovalent for CD28 binding and methods of useBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Feb 16, 2021·3 cites·18 claims
- 1091US9228018B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jan 5, 2016·11 cites·35 claims
- 1188US9908937B2Compositions monovalent for CD28 binding and methods of useBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Mar 6, 2018·5 cites·22 claims
- 1288US9765150B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 19, 2017·5 cites·37 claims
- 1388US8981072B2Nucleic acids encoding antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Mar 17, 2015·8 cites·27 claims
- 1486US11267888B2Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28BRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 8, 2022·2 cites·6 claims
- 1580US7244573B2Polynucleotides and polypeptides associated with the development of rheumatoid arthritisBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Jul 17, 2007·14 cites·6 claims
- 1680US5877282APeptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereofBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Mar 2, 1999·47 cites·17 claims
- 1778US10196451B2Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40LBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Feb 5, 2019·1 cites·20 claims
- 1878US2022073636A1Antibody polypeptides that antagonize cd40lBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1976US12012452B2Compositions monovalent for CD28 binding and methods of useBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Jun 18, 2024·0 cites·20 claims
- 2075US6869956B2Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)BRISTOL MYERS SQUIBB CO·Filed 2002·Granted Mar 22, 2005·9 cites·4 claims
- 2173US11912769B2Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28BRISTOL MYERS SQUIBB CO·Filed 2022·Granted Feb 27, 2024·0 cites·15 claims
- 2271US11180567B2Antibody polypeptides that antagonize CD40LBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 23, 2021·0 cites·20 claims
- 2371US2025129137A1Cd71 binding fibronectin type iii domainsARO BIOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 2468US2023236188A1Methods of diagnosing and treating lupusBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2567US7670785B2Polynucleotides and polypeptides associated with the development of rheumatoid arthritisBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Mar 2, 2010·0 cites·4 claims
- 2666US5962415ACompositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereofBRISTOL MYERS SQUIBB CO·Filed 1998·Granted Oct 5, 1999·28 cites·17 claims
- 2765US2025368997A1Compositions and Methods for GYS1 InhibitionAro Biotherapeutics Company·Filed 2023·Application pending·0 cites
- 2863US2024043844A1FN3 Domain-siRNA Conjugates with Enzyme Replacement TherapyAro Biotherapeutics Company·Filed 2023·Application pending·0 cites
- 2963US2024175034A1Fn3 domain-sirna conjugates and uses thereofAro Biotherapeutics Company·Filed 2023·Application pending·0 cites
- 3061US7442554B2Compositions and methods involving glucocorticoid receptor site IIBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Oct 28, 2008·0 cites·7 claims
- 3161US2025281622A1FN3 DOMAIN-siRNA CONJUGATES AND USES THEREOFAro Biotherapeutics Company·Filed 2025·Application pending·0 cites
- 3258US12491255B2EPCAM binding fibronectin type III domainsAro Biotherapeutics Company·Filed 2020·Granted Dec 9, 2025·0 cites·13 claims
- 3357US2020231676A1Methods of treating transplant rejection using a domain antibody directed against cd40lBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3454US2010119509A1Polynucleotides and polypeptides associated with the development of rheumatoid arthritisBRISTOL MYERS SQUIBB CO·Filed 2010·Application pending·0 cites
- 3551US2004171823A1Polynucleotides and polypeptides associated with the NF-kappaB pathwayFiled 2004·Application pending·0 cites
- 3650US6730302B1Intracellular targeted delivery of compounds by 70 kD heat shock proteinBRISTOL MYERS SQUIBB CO·Filed 1999·Granted May 4, 2004·9 cites·35 claims
- 3750US2019086405A1Methods of diagnosing and treating lupusBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 3849US2004086896A1Polynucleotides and polypeptides associated with the NF-kB pathwayFiled 2003·Application pending·0 cites
- 3949US2017051059A1Methods of treating transplant rejection using a domain antibody directed against cd40BRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 4048US2003170743A1Polynucleotides and polypeptides associated with the development of osteoarthritisFiled 2002·Application pending·0 cites
- 4145US2003224486A1Polynucleotides and polypeptides associated with the NF-kB pathwayFiled 2002·Application pending·0 cites
- 4243US2017240636A1Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28BRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 4335US2003190613A1Polynucleotide encoding an activated human T-lymphocyte-derived protein related to ubiquitin conjugating enzymeFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Steven G. Nadler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →